Evidence map›Paper›PMID 42621284›Full record

ArticlePostepy dermatologii i alergologii2026

TRAF3IP2 (rs13190932) polymorphism in psoriasis and psoriatic arthritis: susceptibility, systemic inflammation and response to methotrexate.

Eisa M Hegazy, Moustafa A El Taieb, Mohammed H Hassan, Mahmoud Ahmed Ali, Shimaa S Ahmed, Eslam A Sadek, Ebtehal A Kotop, Fawzia Mohamed Abd Elzaher, Soheir Abdel-Hamid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Postepy dermatologii i alergologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eisa M HegazyDermatology, Venereology and Andrology Department, Faculty of Medicine, Qena University, Qena, Egypt.
Moustafa A El TaiebDermatology, Venereology, and Andrology Department, Faculty of Medicine, Aswan University, Aswan, Egypt.
Mohammed H HassanDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Qena University, Qena, Egypt.
Mahmoud Ahmed AliDermatology, Venereology, and Andrology Department, Faculty of Medicine, Aswan University, Aswan, Egypt.
Shimaa S AhmedRheumatology and Rehabilitation Department, Faculty of Medicine, Luxor University, Luxor, Egypt.
Eslam A SadekDepartment of Public Health and Community Medicine, Faculty of Medicine, Qena University, Qena, Egypt.
Ebtehal A KotopDermatology, Venereology and Andrology Department, Faculty of Medicine, Qena University, Qena, Egypt.
Fawzia Mohamed Abd ElzaherDermatology, Venereology and Andrology Department, Faculty of Medicine, Qena University, Qena, Egypt.
Soheir Abdel-HamidDermatology, Venereology and Andrology Department, Faculty of Medicine, Qena University, Qena, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated inflammatory disorders. The TRAF3IP2 gene encodes Act1, a crucial adaptor protein in interleukin-17 signalling, which is fundamental to the pathophysiology of psoriasis and psoriatic arthritis. Aim: To examine the correlation between the TRAF3IP2 (rs13190932) polymorphism and the susceptibility to psoriasis and PsA. Material and methods: This prospective observational cohort study enrolled 120 patients with psoriasis, comprising 40 with PsA, alongside 40 age- and sex-matched healthy controls. The Psoriasis Area and Severity Index (PASI) and the Disease Activity Index for Psoriatic Arthritis (DAPSA) were used. Real-time polymerase chain reaction was used to genotype TRAF3IP2 (rs13190932). We used non-parametric statistical analyses. Results: Patients with psoriasis showed markedly elevated inflammatory markers and metabolic irregularities in comparison to controls. The AA genotype and A allele of TRAF3IP2 (rs13190932) were substantially more prevalent in patients with psoriasis and psoriatic arthritis, indicating heightened disease vulnerability. There was a positive correlation between disease severity and systemic inflammatory markers. After 12 weeks of treatment with methotrexate, the PASI and DAPSA scores significantly decreased. There was no notable correlation between TRAF3IP2 genotypes and illness severity or therapy response. Conclusions: The TRAF3IP2 (rs13190932) polymorphism is substantially linked to susceptibility to psoriasis and psoriatic arthritis, but not to disease severity or short-term response to methotrexate. Methotrexate continues to be an effective short-term systemic treatment for both diseases.

Indexed as

methotrexatepolymorphismpsoriasispsoriatic arthritisTRAF3IP2

Identifiers

PMID42621284
PMCPMC13487572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.